NCT07797790Recruiting
Real-world Patient Experiences With Inbrija®
Real-world Patient Experiences With Inbrija® - Non-interventional Assessment of Inhaled Levodopa for the Management of OFF Episodes in Parkinson's Disease: a Mixed-methods Study
Source: ClinicalTrials.gov · Last updated 2 Oct 2026
Brief summary (registry, in English)
Parkinson's disease can cause OFF episodes, when medication effects wear off and symptoms return, affecting movement, daily activities, comfort, and wellbeing. This study aims to explore the experiences of people with Parkinson's disease who are prescribed Inbrija® as part of their usual care. Through a mixed-methods approach, the study will examine how OFF episodes affect patients, what influences their decision to use Inbrija®, and whether patient-reported outcomes related to symptoms, daily functioning, and quality of life change during the first 3 months of treatment. The study is planned to be conducted at approximately 7 sites in Austria, Germany, and Sweden and will enroll up to 120 participants receiving Inbrija® in routine clinical practice.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 27 Aug 2026
- Start date
- Sept 2026
- Primary completion date
- Aug 2027
- Lead sponsor
- Merz Therapeutics GmbH
- Diseases
- Parkinson disease
- NCT number
- NCT07797790
What you commit to
- Study type: Observational
- Planned participants: 120
- From Sept 2026 to the primary completion date, Aug 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous use of Inbrija® before study enrollment.
- Participation in an interventional Parkinson's disease clinical trial within 3 months prior to Inbrija® initiation.
- Participation in an interventional Parkinson's disease clinical trial within 3 months prior to enrollment.
Other
- For the Quantitative Component:
- Residence outside Austria, Germany, or Sweden.
- Current use of an on-demand treatment for OFF episodes other than Inbrija®.
- For the Qualitative Component:
- Residence outside Austria or Germany.
- Current use of an on-demand treatment for OFF episodes other than Inbrija®.
Who the study is looking for
- Adults aged 18 years or older.
- Diagnosis of Parkinson's disease with a history of OFF episodes.
- Able and willing to provide informed consent.
- For the Quantitative Component:
- Physician decision to initiate Inbrija® for the treatment of OFF episodes in Parkinson's disease according to routine clinical practice prior to enrollment.
- For the Qualitative Component:
- Current user of Inbrija® for OFF episodes in Parkinson's disease according to approved prescribing conditions.
- At least 6 weeks of regular Inbrija® use (minimum 4 uses during the previous month).
- Able to participate in a 60-minute interview using an internet-enabled device.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Neurologisches Therapiezentrum Gmundnerberg GmbH Coordinator of this site? Confirm its status | Altmünster | Austria | Not yet recruiting |
| Medizinischen Universität Graz Coordinator of this site? Confirm its status | Graz | Austria | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.